Drug intelligence / Profile preview

UIV011

Development stage: Preclinical
Lead developer: UTC Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

UIV011 is an investigational in vivo CAR-T cell therapy developed by UTC Therapeutics for the treatment of glypican-3 (GPC3)-positive hepatocellular carcinoma. Utilizing UTC's proprietary LACO-Stim® technology, UIV011 is designed to engineer T cells directly within the patient's body to express chimeric antigen receptors (CARs) specific to GPC3. This approach aims to eliminate the complex and costly ex vivo manufacturing process associated with traditional CAR-T therapies while leveraging enhanced co-stimulation to improve the anti-tumor response and persistence of the generated CAR-T cells. It is currently in preclinical development.

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on UIV011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UIV011.

Explore the full profile